Gorfinkel, L. R., Malte, C. A., Fink, D. S., Mannes, Z. L., Wall, M. M., Olfson, M., Livne, O., Keyhani, S., Keyes, K. M., Martins, S. S., Cerdá, M., Gutkind, S., Maynard, C. C., Saxon, A. J., Simpson, T., Gonsalves, G., Lu, H., McDowell, Y., & Hasin, D. S. (2024). Trends in Opioid Use Disorder in the Veterans Health Administration, 2005-2022. JAMA Network Open, 7(12), e2451821. https://doi.org/10.1001/jamanetworkopen.2024.51821

Freisthler, B., Chahine, R. A., Villani, J., Chandler, R., Feaster, D. J., Slavova, S., Defiore-Hyrmer, J., Walley, A. Y., Kosakowski, S., Aldridge, A., Barbosa, C., Bhatta, S., Brancato, C., Bridden, C., Christopher, M., Clarke, T., David, J., D’Costa, L., Ewing, I., … Oga, E. A. (2024). Communities That HEAL Intervention and Mortality Including Polysubstance Overdose Deaths. JAMA Network Open, 7(10), e2440006. https://doi.org/10.1001/jamanetworkopen.2024.40006

Ross, R. K., Inose, S., Shulman, M., Nunes, E. V., Zalla, L. C., Burlew, A. K., & Rudolph, K. E. (2024). Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity. JAMA Network Open, 7(10), e2436612. https://doi.org/10.1001/jamanetworkopen.2024.36612

Hayes, C. J., Raciborski, R. A., Nowak, M., Acharya, M., Nunes, E. V., & Winhusen, T. J. (2024). Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type. Addiction. Portico. https://doi.org/10.1111/add.16659

Nunes, E. V., Comer, S. D., Lofwall, M. R., Walsh, S. L., Peterson, S., Tiberg, F., Hjelmstrom, P., & Budilovsky-Kelley, N. R. (2024). Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use. JAMA Network Open, 7(6), e2417377. https://doi.org/10.1001/jamanetworkopen.2024.17377

Richardson, M., Hirchak, K., Bajet, K., Brigman, M., Shaffer, R., Keyes, B., Oliver, K. A., Kropp, F., McDonell, M. G., Venner, K. L., & Campbell, A. N. C. (2024). Provider perspectives on the impact of COVID-19 on treatment of substance use and opioid use disorders among American Indian and Alaska Native adults. Frontiers in Public Health, 12. https://doi.org/10.3389/fpubh.2024.1356033

Lichtiger, A. B., Deng, Y., Zhang, C., Groeger, J., Perez, H. R., Nangia, G., Prinz, M., Richard, E., Glenn, M., De La Cruz, A. A., Pazmino, A., Cunningham, C. O., Amico, K. R., Fox, A., & Starrels, J. L. (2024). Incarceration history and opioid use among adults living with HIV and chronic pain: a secondary analysis of a prospective cohort study. Health & Justice, 12(1). https://doi.org/10.1186/s40352-024-00272-x

Williams, A. R., Rowe, C., Minarik, L., Gray, Z., Murphy, S. M., & Pincus, H. A. (2024). Use of in-network insurance benefits is critical for improving retention in telehealth-based buprenorphine treatment. Health Affairs Scholar, 2(3). https://doi.org/10.1093/haschl/qxae009

Otufowora, A., Egan, K. L., Chaudhari, P. V., Okusanya, A. A., Ogidan, A. O., & Cottler, L. B. (2023). Drug Deactivation Pouches for Primary Prevention of Opioid Overdose: Perceptions and Attitudes of Community Members. The Journal of the American Board of Family Medicine, 37(1), 112–117. https://doi.org/10.3122/jabfm.2023.230227r1

Young, A., Sinicrope, P., Kelpin, S., Roche, A. I., Sabaque, C., Pham, C., Marsch, L. A., Campbell, A. N. C., Venner, K., Bastian, E., Nord, T., Mason, G., Baker, L., Wyatt, T., Fish, A., Bart, G., & Patten, C. A. (2023). Wiidookaage’Win: A Community-Based Qualitative Approach to Developing a Facebook Group Intervention for Native Women to Support Recovery From Opioid Use. American Journal of Health Promotion, 38(2), 205–218. https://doi.org/10.1177/08901171231205355

Mariani, J. J., Dobbins, R. L., Heath, A., Gray, F., & Hassman, H. (2023). Open‐label investigation of rapid initiation of extended‐release buprenorphine in patients using fentanyl and fentanyl analogs. The American Journal on Addictions, 33(1), 8–14. Portico. https://doi.org/10.1111/ajad.13484

Bushnell, G. A., Rynn, M. A., Gerhard, T., Keyes, K. M., Hasin, D. S., Cerdá, M., Nyandege, A., & Olfson, M. (2023). Drug overdose risk with benzodiazepine treatment in young adults: Comparative analysis in privately and publicly insured individuals. Addiction, 119(2), 356–368. Portico. https://doi.org/10.1111/add.16359

Sacco, D., Probst, M., Martins, S., Comer, S., & Chang, B. (2023). 300 Prevalence of Fentanyl Co-Ingestion Among Emergency Department Patients With Opioid and Non-Opioid Drug Overdoses. Annals of Emergency Medicine, 82(4), S131. https://doi.org/10.1016/j.annemergmed.2023.08.324

Uusküla, A., Raag, M., Barnes, D. M., Tross, S., Ave, T., & Des Jarlais, D. C. (2023). Adapted “Break the Cycle for Avant Garde” intervention to reduce injection assisting and promoting behaviours in people who inject drugs in Tallinn, Estonia: A pre- post trial. PLOS ONE, 18(5), e0266815. https://doi.org/10.1371/journal.pone.0266815

Wilkerson, A. H., Sharma, M., Davis, R. E., Stephens, P. M., Kim, R. W., Bhati, D., & Nahar, V. K. (2023). Predisposing, enabling and reinforcing factors associated with opioid addiction helping behaviour in tri-state Appalachian counties: application of the PRECEDE–PROCEED model–cross-sectional analysis. BMJ Open, 13(5), e066147. https://doi.org/10.1136/bmjopen-2022-066147

Marziali, M. E., Giordano, M., Gleit, Z., Prigoff, J., Landau, R., & Martins, S. S. (2023). Development and design of a mobile application for prescription opioid clinical decision-making: a feasibility study in New York City, USA. BMJ Open, 13(2), e066427. https://doi.org/10.1136/bmjopen-2022-066427

Williams, A. R., Aronowitz, S., Gallagher, R., Behar, E., Gray, Z., & Bisaga, A. (2022). A Virtual-First Telehealth Treatment Model for Opioid Use Disorder. Journal of General Internal Medicine, 38(3), 814–816. https://doi.org/10.1007/s11606-022-07955-x

Hirchak, K. A., Amiri, S., Kordas, G., Oluwoye, O., Lyons, A. J., Bajet, K., Hahn, J. A., McDonell, M. G., Campbell, A. N. C., & Venner, K. (2022). Variations in national availability of waivered buprenorphine prescribers by racial and ethnic composition of zip codes. Substance Abuse Treatment, Prevention, and Policy, 17(1). https://doi.org/10.1186/s13011-022-00457-3

Petrakis, I., Springer, S. A., Davis, C., Ralevski, E., Gu, L., Lew, R., Hermos, J., Nuite, M., Gordon, A. J., Kosten, T. R., Nunes, E. V., Rosenheck, R., Saxon, A. J., Swift, R., Goldberg, A., Ringer, R., & Ferguson, R. (2022). Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Addiction Science & Clinical Practice, 17(1). https://doi.org/10.1186/s13722-022-00286-6

Mannes, Z. L., Stohl, M., Fink, D. S., Olfson, M., Keyes, K. M., Martins, S. S., Gradus, J. L., Saxon, A. J., Maynard, C., Livne, O., Gutkind, S., & Hasin, D. S. (2022). Non-pharmacological Treatment for Chronic Pain in US Veterans Treated Within the Veterans Health Administration: Implications for Expansion in US Healthcare Systems. Journal of General Internal Medicine, 37(15), 3937–3946. https://doi.org/10.1007/s11606-021-07370-8